CSI Market
Sign In | Register

Sab Biotherapeutics Inc (SABS) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access SABS quarterly Cash Flow →
Cash flow patterns shown here provide context for understanding Sab Biotherapeutics Inc's ability to sustain operations and capital deployment.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income13.27
Depreciation & amortization2.99
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment0.00
Share-based Compensation5.21
Income (Loss) from Equity Method Investments0.00
Fair Value Adjustment of Warrants-62.75
Interest Earned On Marketable Securities Held In Trust Account-
Amortization Of Rightofuse Assets-
Increase Decrease In Operating Lease Right Of Use Assets-
Rightofuse Assets Amortization-
Gain Loss On Termination Of Lease-
Increase Decrease In Operating Lease Rightofuse Assets-
Increase Decrease In Accrued Expenses And Other Current Liabilities0.94
Gain Loss On Private Placement Issuance-
Gain From Private Placement Warrant Termination-
Finance Lease Right Of Use Asset Amortization0.09
Write Off Of Deferred Issuance Costs0.26
Equity Securities Fv Ni Gain Loss0.07
Debt Securities Realized Gain Loss-
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accrued Interest Receivable, Net-0.89
Increase (Decrease) in Accounts Payable1.48
Increase (Decrease) in Accrued Liabilities0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-5.29
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-0.16
Discontinued operations0.00
Net Cash flow from Operating Activities-44.78
Investing Activities
Capital Expenditures-0.93
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Marketable Securities21.26
Payments to Acquire Available-for-sale Securities, Debt-142.04
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Proceeds from Sales of Business, Affiliate and Productive Assets0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-121.71
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments-0.28
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net166.30
Payment Of Deferred Offering Costs-
Proceeds From Sale Of Units Net Of Underwriting Discounts-
Proceeds From Sale Of Representative Shares-
Proceeds From Paycheck Protection Program S B A Loan-
Repayments Of Notes Payable Excluding Related Party Notes Payable-
Finance Lease Principal Payments-0.14
Right Of Use Asset Obtained In Exchange For Operating Lease Liability2.42
Warrant Liabilities Assumed Related To Business Combination-
Liabilities Assumed Related To Forward Share Purchase Agreement-
Financing Fee Liabilities Assumed Related To The Merger Included In Accrued Expense And Other Current Liabilities-
Unpaid Financing Fees Included In Accrued Expense And Other Current Liabilities-
Payment Of Deferred Issuance Costs0.00
Net Proceeds From Issuance Of Public Offering-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities168.30
Effect of exchange rate on cash flow-0.21
Discontinued operations0.00
Free Cash Flow-45.71
Total Cash Flow1.60
4 historic quarters locked

Sign in to unlock the full Sab Biotherapeutics Inc cash flow history.

Sign In Create Free Account

About Sab Biotherapeutics Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001833214-26-000003

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License